Opus Genetics vs Precigen
IRD and PGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and PGEN compare
Precigen is the larger company, worth 4.9 times as much as Opus Genetics ($1.6B against $331M).
Precigen keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with −1727% at Opus Genetics.
Precigen scores higher on the StockData Score (6 against 5 for Opus Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | PGEN |
|---|---|---|
| Size and price | ||
| Market cap | $331M | $1.6B |
| Share price | $3.98 | $4.54 |
| Change, 1 year | 107% | 12.9% |
| Change, 5 years | 9.3% | 20.7% |
| Beta (5Y) | 0.97 | 1.63 |
| Employees | 27 | 20 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 4 (better) |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 114× |
| P/S | 41.8× | 10.4× (better) |
| P/B | 8.6× (better) | 19.4× |
| EV/EBITDA | – | 43.8× |
| FCF yield | – | −4.6% |
| Fair value | $0.711 | $1.34 |
| Margin of safety | −460% | −239% (better) |
| Growth | ||
| Revenue growth (TTM) | −45.9% | – |
| Revenue growth, 5Y average | – | −21.3% |
| Profitability | ||
| Operating margin | −778% | 21.4% (better) |
| Net margin | −1727% | 15.6% (better) |
| FCF margin | – | −47.4% |
| Return on equity | −616% | 38.8% (better) |
| Return on invested capital | – | 147% |
| Financial health | ||
| Debt / equity | 0.00 | 1.12 (better) |
| Net debt / EBITDA | – | 1.14 |
| Interest coverage | −217.5× | 2.8× (better) |
| Current ratio | 9.65 (better) | 5.58 |
| Altman Z-score | −2.02 (better) | −5.48 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.73% | 0.00% (better) |
| Shareholder yield | −0.73% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.8% | 39.2% |
| Held by insiders | 37.6% | 44.9% |
| Insider net buying, 12 months | −$19.4M (better) | −$32.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 20.9% | 22.8% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.